文献速递淋巴瘤造血干细胞移植与细胞治疗

CAR-T细胞联合限时伊布替尼治疗复发/难治性套细胞淋巴瘤:2期TARMAC研究

CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study.
PubMed 文献 · Blood · 2024-01-01

2期TARMAC研究评估限时伊布替尼联合CTL019 CAR-T治疗20例复发/难治性套细胞淋巴瘤患者,主要终点4个月完全缓解率达80%,13个月中位随访时估计12个月无进展生存率75%、总生存率100%,细胞因子释放综合征发生15例(75%),疗效不受既往BTK抑制剂暴露或TP53突变影响。

要点

  • 限时伊布替尼联合CTL019 CAR-T在复发/难治性套细胞淋巴瘤中4个月完全缓解率达80%。
  • 13个月中位随访时估计12个月无进展生存率75%、总生存率100%。
  • 细胞因子释放综合征发生15例(75%),其中3级3例(20%),1-2级可逆性神经毒性2例(10%)。

核心结论

  • BTK抑制剂与T细胞重定向免疫治疗联合的安全性和疗效看起来有前景,值得进一步探索。

研究设计与样本

  • 2期TARMAC研究纳入20例套细胞淋巴瘤患者,评估限时伊布替尼联合CTL019 CAR-T治疗。
  • 伊布替尼在白细胞分离前开始,持续至CAR-T制备期间,并在CAR-T输注后至少继续6个月。
  • 中位既往治疗线数为2,50%的患者既往暴露于Bruton酪氨酸激酶抑制剂(BTKi)。
  • 主要终点为输注后4个月完全缓解率,次要终点包括安全性和基于TP53异常的亚组分析。

主要发现

  • 主要终点达到,80%的患者显示完全缓解,70%和40%的患者分别通过流式细胞术和分子方法检测到可测量残留病灶阴性。
  • 13个月中位随访时,估计12个月无进展生存率为75%,总生存率为100%。
  • 15例患者(75%)发生细胞因子释放综合征,其中12例(55%)为1-2级,3例(20%)为3级。
  • 2例患者(10%)观察到可逆性1-2级神经毒性。
  • 无论既往BTKi暴露或TP53突变,疗效均保持。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD19-directed chimeric antigen receptor T cells (CAR-T) achieve high response rates in patients with relapsed/refractory mantle cell lymphoma (MCL). However, their use is associated with significant toxicity, relapse concern, and unclear broad tractability. Preclinical and clinical data support a beneficial synergistic effect of ibrutinib on apheresis product fitness, CAR-T expansion, and toxicity. We evaluated the combination of time-limited ibrutinib and CTL019 CAR-T in 20 patients with MCL in the phase 2 TARMAC study. Ibrutinib commenced before leukapheresis and continued through CAR-T manufacture for a minimum of 6 months after CAR-T administration. The median prior lines of therapy was 2; 50% of patients were previously exposed to a Bruton tyrosine kinase inhibitor (BTKi). The primary end point was 4-month postinfusion complete response (CR) rate, and secondary end points included safety and subgroup analysis based on TP53 aberrancy. The primary end point was met; 80% of patients demonstrated CR, with 70% and 40% demonstrating measurable residual disease negativity by flow cytometry and molecular methods, respectively. At 13-month median follow-up, the estimated 12-month progression-free survival was 75% and overall survival 100%. Fifteen patients (75%) developed cytokine release syndrome; 12 (55%) with grade 1 to 2 and 3 (20%) with grade 3. Reversible grade 1 to 2 neurotoxicity was observed in 2 patients (10%). Efficacy was preserved irrespective of prior BTKi exposure or TP53 mutation. Deep responses correlated with robust CAR-T expansion and a less exhausted baseline T-cell phenotype. Overall, the safety and efficacy of the combination of BTKi and T-cell redirecting immunotherapy appears promising and merits further exploration. This trial was registered at www.ClinicalTrials.gov as #NCT04234061.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Minson A, Hamad N, Cheah CY, et al. CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study. Blood. 2024. PMID: 37883795. doi:10.1182/blood.2023021306

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。